PDCD1 and neoplasm: Consistent with previous studies, the in vitro and in vivo studies conducted by Li and colleagues corroborated that anti-HER2 CAR-T cells combined with anti-PD-1 antibodies could secrete more IL-2 and IFN-γ, effectively killing tumor cells [72].